Fujimoto, Daichi
Miura, Satoru
Tomii, Keisuke
Sumikawa, Hiromitsu
Yoshimura, Kenichi
Wakuda, Kazushige
Oya, Yuko
Yokoyama, Toshihide
Kijima, Takashi
Asao, Tetsuhiko
Tamiya, Motohiro
Nakamura, Atsushi
Yoshioka, Hiroshige
Tokito, Takaaki
Murakami, Shuji
Tamiya, Akihiro
Yokouchi, Hiroshi
Watanabe, Satoshi
Yamaguchi, Ou
Morinaga, Ryotaro
Jodai, Takayuki
Ito, Kentaro
Shiraishi, Yoshimasa
Kogure, Yoshihito
Shibaki, Ryota
Yamamoto, Nobuyuki
Article History
Received: 4 October 2022
Accepted: 28 February 2023
First Online: 6 March 2023
Competing interests
: Aside from the submitted work, Daichi Fujimoto reports grants and personal fees from AstraZeneca K.K. and Boehringer Ingelheim Japan Inc.; and personal fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K, Eli Lilly Japan K.K., and Novartis Pharma K.K; Satoru Miura reports personal fees from AstraZeneca K.K., Bristol-Myers Squibb Co., Ltd., Boehringer Ingelheim, MSD K.K., Elli Lilly Japan, Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd; Keisuke Tomii reports consulting fees from Elli Lilly Japan and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K., and Taiho Pharmaceutical Co., Ltd; Kazushige Wakuda reports receiving grants and personal fees from Chugai Pharmaceutical Co., Ltd. and AstraZeneca K.K.; grants from Novartis, Daiichi Sankyo, and AbbVie; and personal fees from Taiho Pharmaceutical Co., Ltd, Boehringer Ingelheim, Eli Lilly K.K., Ono Pharmaceutical Co., Ltd, and MSD K.K; Yuko Oya reports receiving personal fees from AstraZeneca K.K., MSD K.K., Takeda Co. Ltd., Taiho Pharmaceutical Co. Ltd., Amgen Co. Ltd., and Eli Lilly Japan K.K; Toshihide Yokoyama reports receiving grants from Bristol-Myers Squibb Co., Ltd., MSD K.K., and Chugai Pharmaceutical Co., Ltd.; and personal fees from Bristol-Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd., MSD K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., and AstraZeneca K.K; Tetsuhiko Asao reports receiving personal fees from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Ono Pharmaceutical Co., Ltd; Motohiro Tamiya reports receiving grants from Boehringer Ingelheim, Bristol-Myers Squibb Co., and Ono Pharmaceutical Co., Ltd.; and personal fees from Chugai Pharmaceutical Co., Ltd, AstraZeneca, Eli Lilly, Pfizer, Ono Pharmaceutical Co., Ltd, and Asahi Kasei Pharmaceutical; Atsushi Nakamura reports receiving personal fees from AstraZeneca K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Kyowa Kirin Co., Ltd., Thermo Fisher Scientific, Novartis Pharma K.K., and Pfizer Inc; Hiroshige Yoshioka reports receiving personal fees from MSD K.K., Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., Ltd., Delta-Fly Pharma, Otsuka Pharmaceutical Co., Ltd., Novartis, Pfizer, Takeda Pharmaceutical Co., Ltd., and Merck Biopharma Co., Ltd; Takaaki Tokito reports receiving personal fees from Chugai Pharmaceutical Co., Ltd., AstraZeneca, MSD K.K., and Novartis; Shuji Murakami reports receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis, and Merck; Akihiro Tamiya reports receiving grants from AstraZeneca K.K. and National Hospital Organization (Japan) and personal fees from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Boehringer Ingelheim Japan Inc, Eli Lilly Japan K.K., Kyowa Kirin, Pfizer, Kissei, Takeda Pharmaceutical Co., Ltd., Novartis, and Merck Biopharma; Hiroshi Yokouchi reports receiving grants from Chugai Pharmaceuticals Co., Ltd., AstraZeneca, AbbVie, Daiichi Sankyo, Bristol-Myers Squibb Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Sanofi; and personal fees from Chugai Pharmaceutical Co., Ltd. and AstraZeneca; Satoshi Watanabe reports receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co., Ltd., Boehringer Ingelheim, Eli Lilly, MSD K.K., Taiho Pharmaceutical Co., Ltd., Pfizer, Novartis, Daiichi Sankyo, and Nippon Kayaku; Ou Yamaguchi reports receiving personal fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co., Ltd., and Chugai Pharmaceutical Co., Ltd; Kentaro Ito reports receiving personal fees from Eli Lilly, Boehringer Ingelheim, AstraZeneca, MSD K.K., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer; Yoshimasa Shiraishi reports receiving grants from Chugai Pharmaceutical Co., Ltd., and personal fees from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and AstraZeneca; Yoshihito Kogure reports receiving grants from MSD K.K. and personal fees from AstraZeneca, MSD K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim, and Eli Lilly; Nobuyuki Yamamoto reports receiving personal fees from Chugai Pharmaceutical Co., Ltd., MSD K.K., AstraZeneca, Ono Pharmaceutical Co., Ltd., Thermo Fisher Scientific, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Boehringer Ingelheim., Novartis., Pfizer Inc., Bristol-Myers Squibb Co., Ltd., Nippon Kayaku, GlaxoSmithKline K.K., Sanofi K.K., Hisamitsu Pharmaceutical Co., Inc., Life Technologies Japan Ltd., Amgen Inc., Guardant Health Japan, Janssen Pharmaceutical K.K. and Merck Biopharma; and has leadership or fiduciary role in the Japan Lung Cancer Society, Japanese Association of Supportive Care in Cancer, and the West Japan Oncology Group. The remaining authors declare no conflict of interest.